The cysteine-containing cell-penetrating peptide AP delivered CTLA-4 peptide cargo into T cells both in vitro and in vivo, reducing pathogenic Th17 cells and ameliorating experimental autoimmune encephalomyelitis — a model for multiple sclerosis.
T cells + BBB penetrationAP peptide delivers cargo into T cells AND crosses the blood-brain barrier — enabling direct immune cell modulation in the CNS for autoimmune brain diseases
What the researchers found
AP CPP (9 amino acids with one cysteine) delivered EGFP to human T cells and biodistributed to spleen, liver, intestines, and brain after systemic administration. AP-ctCTLA-4 reduced Th17 differentiation in vitro and ameliorated EAE with decreased IL-17A+GM-CSF+ CD4 T cells in vivo.
Why it matters
T cell-targeted drug delivery is a holy grail of immunotherapy. A CPP that delivers regulatory peptides into T cells AND crosses the blood-brain barrier could treat MS and other autoimmune conditions more effectively than current drugs.
The numbers in context
9-AA optimal CPP sequence; crossed BBB; reduced IL-17A+ GM-CSF+ CD4 T cells in EAE
How the study worked
In vitro and in vivo study. AP peptide sequence optimization for T cell delivery. Biodistribution after systemic administration. AP-ctCTLA-4 conjugate tested for Th17 suppression in vitro and EAE amelioration in vivo. Flow cytometry for T cell phenotyping.
Who was studied
Mice with experimental autoimmune encephalomyelitis; human T cells in vitro
What this study cannot tell us
Mouse EAE model — human MS is more complex. Systemic AP delivery may have off-target effects in other tissues. CTLA-4 pathway modulation could cause immunosuppression. Long-term safety not assessed. Peptide stability in circulation unknown.
How to read the evidence
Moderate evidence: combined in vitro and in vivo data with disease model efficacy and biodistribution. EAE model limitations apply.
When this study was published
Published 2021. CPP-based T cell delivery platforms continue advancing toward clinical applications.
The bigger picture
Intracellular delivery to specific immune cells represents the next frontier in autoimmune therapy. AP's ability to deliver functional immune checkpoint molecules directly into T cells — including in the brain — opens possibilities far beyond current antibody-based immunotherapies.
Questions still open
- Would AP-CTLA-4 be as effective as injectable CTLA-4 antibodies (like abatacept) with fewer systemic side effects?
- Can AP deliver other regulatory molecules to T cells for different autoimmune diseases?
- Does AP's blood-brain barrier penetration enable CNS-specific immune modulation?
Common questions
Why is delivering drugs to T cells so important?
Could this treat multiple sclerosis?
Read the original research
The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis.
Pharmaceutics, 13(8)
Citation
Kim, Won-Ju; Kim, Gil-Ran; Cho, Hyun-Jung; Choi, Je-Min. (2021). The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis.. Pharmaceutics, 13(8). https://doi.org/10.3390/pharmaceutics13081134